XEM:CA:TSX-iShares MSCI Emerging Markets Index ETF (CAD)

ETF | Emerging Markets Equity |

Last Closing

CAD 34.39

Change

+0.18 (+0.53)%

Market Cap

CAD 0.20B

Volume

3.80K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Emerging Markets Equity

Symbol Name Price(Change) Market Cap
XSEM:CA iShares ESG MSCI Emerging Mark..

+0.13 (+0.60%)

CAD 3.14B
XEC:CA iShares Core MSCI Emerging Mar..

+0.14 (+0.47%)

CAD 1.80B
ZEM:CA BMO MSCI Emerging Markets Inde..

+0.13 (+0.58%)

CAD 1.07B
DRFE:CA Desjardins RI Emerging Markets..

-0.45 (-1.87%)

CAD 0.08B
XMM:CA iShares MSCI Min Vol Emerging ..

-0.06 (-0.20%)

CAD 0.06B
RXD:CA RBC Quant Emerging Markets Div..

-0.01 (-0.05%)

CAD 0.04B
VEE:CA Vanguard FTSE Emerging Markets

+0.20 (+0.51%)

N/A
ZLE:CA BMO Low Volatility Emerging Ma..

N/A

N/A

ETFs Containing XEM:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Emerging Markets Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.73% 44% F 69% C-
Dividend Return 0.59% 33% F 18% F
Total Return 17.32% 44% F 65% D
Trailing 12 Months  
Capital Gain 21.69% 44% F 57% F
Dividend Return 2.45% 71% C- 42% F
Total Return 24.14% 56% F 56% F
Trailing 5 Years  
Capital Gain 13.42% 44% F 46% F
Dividend Return 7.44% 40% F 26% F
Total Return 20.87% 56% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 1.06% N/A N/A 41% F
Dividend Return 2.61% N/A N/A 42% F
Total Return 1.55% N/A N/A 48% F
Risk Return Profile  
Volatility (Standard Deviation) 15.54% N/A N/A 72% C
Risk Adjusted Return 16.78% N/A N/A 39% F
Market Capitalization 0.20B 57% F 46% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike